Impact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube.
Saved in:
| Title: | Impact of BRCA mutations, age, surgical indication, and hormone status on the molecular phenotype of the human Fallopian tube. |
|---|---|
| Authors: | Beddows I; Department of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA., Djirackor S; Department of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA., Omran DK; Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Jung E; Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Shih NN; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Roy R; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Hechmer A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA., Olshen A; Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA., Adelmant G; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Tom A; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Morrison J; Department of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA., Adams M; Genomics Core, Van Andel Research Institute, Grand Rapids, MI, USA., Rohrer DC; Pathology and Biorepository Core, Van Andel Research Institute, Grand Rapids, MI, USA., Schwartz LE; Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA., Pearce CL; Department of Epidemiology, University of Michigan School of Public Health and Rogel Cancer Center, Ann Arbor, MI, USA., Auman H; Canary Foundation, Palo Alto, CA, USA., Marto JA; Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA.; Blais Proteomics Center, Center for Emergent Drug Targets, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA., Drescher CW; Paul G. Allen Research Center, Swedish Cancer Institute, Seattle, WA, USA. cdresche@fredhutch.org.; Translational Research Program, Fred Hutchinson Cancer Center, Seattle, WA, USA. cdresche@fredhutch.org., Drapkin R; Penn Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. rdrapkin@pennmedicine.upenn.edu.; Basser Center for BRCA, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA. rdrapkin@pennmedicine.upenn.edu., Shen H; Department of Epigenetics, Van Andel Research Institute, Grand Rapids, MI, USA. hui.shen@vai.org. |
| Source: | Nature communications [Nat Commun] 2025 Mar 26; Vol. 16 (1), pp. 2981. Date of Electronic Publication: 2025 Mar 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-025-58145-2 |
